Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat plus dapagliflozin versus baxdrostat alone for albuminuria in chronic kidney disease with hypertension
2025-522407-23-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) and hypertension (HTN) comparing Baxdrostat + Forxiga with Baxdrostat + dapagliflozin placebo (2 arms). Primary endpoint: Change from baseline in urine albumin-to-creatinine ratio at Week 12. Planned start Apr 2026; status: authorised.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on 2025-522407-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522407-23-00.